<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23359361</article-id><article-id pub-id-type="pmc">3687261</article-id><article-id pub-id-type="publisher-id">2294</article-id><article-id pub-id-type="doi">10.2337/dc12-2294</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Clinical Care/Education/Nutrition/Psychosocial Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Effects of a <sc>d</sc>-Xylose Preload With or Without Sitagliptin on Gastric Emptying, Glucagon-Like Peptide-1, and Postprandial Glycemia in Type 2 Diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Tongzhi</given-names></name><degrees>MBBS</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bound</surname><given-names>Michelle J.</given-names></name><degrees>BMED RAD NUC MED</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Beiyi R.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Standfield</surname><given-names>Scott D.</given-names></name><degrees>BSC</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bellon</surname><given-names>Max</given-names></name><degrees>DIP MED TECH AD NUC MED</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Karen L.</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Horowitz</surname><given-names>Michael</given-names></name><degrees>MBBS</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rayner</surname><given-names>Christopher K.</given-names></name><degrees>MBBS</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><aff id="aff1"><sup>1</sup>Discipline of Medicine, University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia</aff><aff id="aff2"><sup>2</sup>Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia</aff><aff id="aff3"><sup>3</sup>Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, Australia</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Chris K. Rayner, <email>chris.rayner@adelaide.edu.au</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>12</day><month>6</month><year>2013</year></pub-date><volume>36</volume><issue>7</issue><fpage>1913</fpage><lpage>1918</lpage><history><date date-type="received"><day>6</day><month>11</month><year>2012</year></date><date date-type="accepted"><day>24</day><month>12</month><year>2012</year></date></history><permissions><copyright-statement>© 2013 by the American Diabetes Association.</copyright-statement><copyright-year>2013</copyright-year><license license-type="creative-commons"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="1913.pdf"></self-uri><abstract><sec><title><offsets xml_i="4955" xml_f="4964" txt_i="11" txt_f="20">OBJECTIVE</offsets></title><p><offsets xml_i="4975" xml_f="5307" txt_i="21" txt_f="353">Macronutrient “preloads” can reduce postprandial glycemia by slowing gastric emptying and stimulating glucagon-like peptide-1 (GLP-1) secretion. An ideal preload would entail minimal additional energy intake and might be optimized by concurrent inhibition of dipeptidyl peptidase-4 (DPP-4). We evaluated the effects of a low-energy </offsets><sc><offsets xml_i="5311" xml_f="5312" txt_i="353" txt_f="354">d</offsets></sc><offsets xml_i="5317" xml_f="5465" txt_i="354" txt_f="502">-xylose preload, with or without sitagliptin, on gastric emptying, plasma intact GLP-1 concentrations, and postprandial glycemia in type 2 diabetes.</offsets></p></sec><sec><title><offsets xml_i="5487" xml_f="5514" txt_i="504" txt_f="531">RESEARCH DESIGN AND METHODS</offsets></title><p><offsets xml_i="5525" xml_f="5718" txt_i="532" txt_f="725">Twelve type 2 diabetic patients were studied on four occasions each. After 100 mg sitagliptin (S) or placebo (P) and an overnight fast, patients consumed a preload drink containing either 50 g </offsets><sc><offsets xml_i="5722" xml_f="5723" txt_i="725" txt_f="726">d</offsets></sc><offsets xml_i="5728" xml_f="5833" txt_i="726" txt_f="831">-xylose (X) or 80 mg sucralose (control [C]), followed after 40 min by a mashed potato meal labeled with </offsets><sup><offsets xml_i="5838" xml_f="5840" txt_i="831" txt_f="833">13</offsets></sup><offsets xml_i="5846" xml_f="5923" txt_i="833" txt_f="910">C-octanoate. Blood was sampled at intervals. Gastric emptying was determined.</offsets></p></sec><sec><title><offsets xml_i="5945" xml_f="5952" txt_i="912" txt_f="919">RESULTS</offsets></title><p><offsets xml_i="5963" xml_f="6063" txt_i="920" txt_f="1020">Both peak blood glucose and the amplitude of glycemic excursion were lower after PX and SC than PC (</offsets><italic><offsets xml_i="6071" xml_f="6072" txt_i="1020" txt_f="1021">P</offsets></italic><offsets xml_i="6081" xml_f="6128" txt_i="1021" txt_f="1065"> &lt; 0.01 for each) and were lowest after SX (</offsets><italic><offsets xml_i="6136" xml_f="6137" txt_i="1065" txt_f="1066">P</offsets></italic><offsets xml_i="6146" xml_f="6224" txt_i="1066" txt_f="1141"> &lt; 0.05 for each), while overall blood glucose was lower after SX than PC (</offsets><italic><offsets xml_i="6232" xml_f="6233" txt_i="1141" txt_f="1142">P</offsets></italic><offsets xml_i="6242" xml_f="6313" txt_i="1142" txt_f="1210"> &lt; 0.05). The postprandial insulin-to-glucose ratio was attenuated (</offsets><italic><offsets xml_i="6321" xml_f="6322" txt_i="1210" txt_f="1211">P</offsets></italic><offsets xml_i="6331" xml_f="6376" txt_i="1211" txt_f="1253"> &lt; 0.05) and gastric emptying was slower (</offsets><italic><offsets xml_i="6384" xml_f="6385" txt_i="1253" txt_f="1254">P</offsets></italic><offsets xml_i="6394" xml_f="6412" txt_i="1254" txt_f="1269"> &lt; 0.01) after </offsets><sc><offsets xml_i="6416" xml_f="6417" txt_i="1269" txt_f="1270">d</offsets></sc><offsets xml_i="6422" xml_f="6512" txt_i="1270" txt_f="1360">-xylose, without any effect of sitagliptin. Plasma GLP-1 concentrations were higher after </offsets><sc><offsets xml_i="6516" xml_f="6517" txt_i="1360" txt_f="1361">d</offsets></sc><offsets xml_i="6522" xml_f="6565" txt_i="1361" txt_f="1404">-xylose than control only before the meal (</offsets><italic><offsets xml_i="6573" xml_f="6574" txt_i="1404" txt_f="1405">P</offsets></italic><offsets xml_i="6583" xml_f="6661" txt_i="1405" txt_f="1480"> &lt; 0.05) but were sustained postprandially when combined with sitagliptin (</offsets><italic><offsets xml_i="6669" xml_f="6670" txt_i="1480" txt_f="1481">P</offsets></italic><offsets xml_i="6679" xml_f="6691" txt_i="1481" txt_f="1490"> &lt; 0.05).</offsets></p></sec><sec><title><offsets xml_i="6713" xml_f="6724" txt_i="1492" txt_f="1503">CONCLUSIONS</offsets></title><p><offsets xml_i="6735" xml_f="6781" txt_i="1504" txt_f="1550">In type 2 diabetes, acute administration of a </offsets><sc><offsets xml_i="6785" xml_f="6786" txt_i="1550" txt_f="1551">d</offsets></sc><offsets xml_i="6791" xml_f="6882" txt_i="1551" txt_f="1642">-xylose preload reduces postprandial glycemia and enhances the effect of a DPP-4 inhibitor.</offsets></p></sec></abstract><counts><page-count count="6"></page-count></counts></article-meta></front><body><p><offsets xml_i="6987" xml_f="7121" txt_i="1651" txt_f="1785">Therapeutic strategies directed at reducing postprandial glycemia are of fundamental importance in the management of type 2 diabetes (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7152" xml_f="7153" txt_i="1785" txt_f="1786">1</offsets></xref><offsets xml_i="7160" xml_f="7268" txt_i="1786" txt_f="1894">). For patients with mild-to-moderate hyperglycemia, postprandial blood glucose is a better predictor of HbA</offsets><sub><offsets xml_i="7273" xml_f="7275" txt_i="1894" txt_f="1896">1c</offsets></sub><offsets xml_i="7281" xml_f="7310" txt_i="1896" txt_f="1925"> than fasting blood glucose (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="7341" xml_f="7342" txt_i="1925" txt_f="1926">2</offsets></xref><offsets xml_i="7349" xml_f="7351" txt_i="1926" txt_f="1928">).</offsets></p><p><offsets xml_i="7358" xml_f="7566" txt_i="1929" txt_f="2137">Both gastric emptying and the action of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are major determinants of postprandial glucose excursions (</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7597" xml_f="7598" txt_i="2137" txt_f="2138">3</offsets></xref><offsets xml_i="7605" xml_f="7823" txt_i="2138" txt_f="2356">). Gastric emptying determines the rate of nutrient delivery to the small intestine, accounting for approximately one-third of the variation in the initial rise in glycemia after oral glucose in both healthy subjects (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="7854" xml_f="7855" txt_i="2356" txt_f="2357">4</offsets></xref><offsets xml_i="7862" xml_f="7896" txt_i="2357" txt_f="2391">) and those with type 2 diabetes (</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7927" xml_f="7928" txt_i="2391" txt_f="2392">5</offsets></xref><offsets xml_i="7935" xml_f="8158" txt_i="2392" txt_f="2615">). GLP-1 and GIP, released predominantly from the distal and proximal gut, respectively, are the known mediators of the incretin effect, whereby much more insulin is stimulated by enteral compared with intravenous glucose (</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="8189" xml_f="8190" txt_i="2615" txt_f="2616">6</offsets></xref><offsets xml_i="8197" xml_f="8253" txt_i="2616" txt_f="2672">). In type 2 diabetes, the incretin effect is impaired (</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="8284" xml_f="8285" txt_i="2672" txt_f="2673">7</offsets></xref><offsets xml_i="8292" xml_f="8399" txt_i="2673" txt_f="2780">), related at least partly to a diminished insulinotropic effect of GIP, while that of GLP-1 is preserved (</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="8430" xml_f="8431" txt_i="2780" txt_f="2781">8</offsets></xref><offsets xml_i="8438" xml_f="8484" txt_i="2781" txt_f="2827">). In addition, GLP-1 slows gastric emptying (</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="8515" xml_f="8516" txt_i="2827" txt_f="2828">9</offsets></xref><offsets xml_i="8523" xml_f="8557" txt_i="2828" txt_f="2862">), suppresses glucagon secretion (</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="8589" xml_f="8591" txt_i="2862" txt_f="2864">10</offsets></xref><offsets xml_i="8598" xml_f="8628" txt_i="2864" txt_f="2894">), and reduces energy intake (</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="8660" xml_f="8662" txt_i="2894" txt_f="2896">11</offsets></xref><offsets xml_i="8669" xml_f="8752" txt_i="2896" txt_f="2979">). Therefore, incretin-based therapies for diabetes have hitherto focused on GLP-1.</offsets></p><p><offsets xml_i="8759" xml_f="9134" txt_i="2980" txt_f="3355">One promising strategy to stimulate endogenous GLP-1 is the “preload” concept, which involves administration of a small load of macronutrient at a fixed interval before a meal so that the presence of nutrients in the small intestine induces the release of gut peptides, including GLP-1, to slow gastric emptying and improve the glycemic response to the subsequent meal. Fat (</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="9166" xml_f="9168" txt_i="3355" txt_f="3357">12</offsets></xref><offsets xml_i="9175" xml_f="9190" txt_i="3357" txt_f="3372">) and protein (</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="9222" xml_f="9224" txt_i="3372" txt_f="3374">13</offsets></xref><offsets xml_i="9231" xml_f="9473" txt_i="3374" txt_f="3616">) preloads achieve these goals but entail additional energy intake. We recently demonstrated in healthy subjects the potential for poorly absorbed sweeteners, which yield little energy, to stimulate GLP-1 secretion and slow gastric emptying (</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="9505" xml_f="9507" txt_i="3616" txt_f="3618">14</offsets></xref><offsets xml_i="9514" xml_f="9516" txt_i="3618" txt_f="3620">).</offsets></p><p><sc><offsets xml_i="9527" xml_f="9528" txt_i="3621" txt_f="3622">d</offsets></sc><offsets xml_i="9533" xml_f="9644" txt_i="3622" txt_f="3733">-Xylose is a pentose sugar, which is incompletely absorbed by passive diffusion in human duodenum and jejunum (</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="9676" xml_f="9678" txt_i="3733" txt_f="3735">15</offsets></xref><offsets xml_i="9685" xml_f="9837" txt_i="3735" txt_f="3887">), with the remainder delivered to the ileum and the colon, where bacterial fermentation occurs, producing hydrogen that can be detected in the breath (</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="9869" xml_f="9871" txt_i="3887" txt_f="3889">16</offsets></xref><offsets xml_i="9878" xml_f="9925" txt_i="3889" txt_f="3936">). We recently showed that oral consumption of </offsets><sc><offsets xml_i="9929" xml_f="9930" txt_i="3936" txt_f="3937">d</offsets></sc><offsets xml_i="9935" xml_f="10049" txt_i="3937" txt_f="4051">-xylose stimulates GLP-1 secretion to a greater and more sustained degree than glucose in healthy older subjects (</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="10081" xml_f="10083" txt_i="4051" txt_f="4053">17</offsets></xref><offsets xml_i="10090" xml_f="10238" txt_i="4053" txt_f="4201">), consistent with the principle that the length and region of small intestine exposed to carbohydrate are important determinants of GLP-1 release (</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="10270" xml_f="10272" txt_i="4201" txt_f="4203">18</offsets></xref><offsets xml_i="10279" xml_f="10282" txt_i="4203" txt_f="4206">). </offsets><sc><offsets xml_i="10286" xml_f="10287" txt_i="4206" txt_f="4207">D</offsets></sc><offsets xml_i="10292" xml_f="10401" txt_i="4207" txt_f="4316">-Xylose also slowed gastric emptying compared with water, with efficacy similar to that of the glucose load (</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="10433" xml_f="10435" txt_i="4316" txt_f="4318">17</offsets></xref><offsets xml_i="10442" xml_f="10444" txt_i="4318" txt_f="4320">).</offsets></p><p><offsets xml_i="10451" xml_f="10581" txt_i="4321" txt_f="4451">Intact GLP-1 is short-lived in the circulation largely because of rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) (</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="10613" xml_f="10615" txt_i="4451" txt_f="4453">19</offsets></xref><offsets xml_i="10622" xml_f="10749" txt_i="4453" txt_f="4580">), and orally administered DPP-4 inhibitors, such as sitagliptin, increase postprandial plasma concentrations of intact GLP-1 (</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="10781" xml_f="10783" txt_i="4580" txt_f="4582">20</offsets></xref><offsets xml_i="10790" xml_f="11122" txt_i="4582" txt_f="4914">). However, the concept of stimulating endogenous GLP-1 with enteral nutrients and then optimizing its action with a DPP-4 inhibitor has received little attention. Moreover, little consideration has been given as to whether the composition of the diet influences the efficacy of DPP-4 inhibition to lower postprandial blood glucose.</offsets></p><p><offsets xml_i="11129" xml_f="11218" txt_i="4915" txt_f="5004">The current study was designed to determine, in patients with type 2 diabetes, whether a </offsets><sc><offsets xml_i="11222" xml_f="11223" txt_i="5004" txt_f="5005">d</offsets></sc><offsets xml_i="11228" xml_f="11398" txt_i="5005" txt_f="5175">-xylose preload would slow gastric emptying, stimulate GLP-1 secretion, and improve postprandial glycemia and whether these effects could be enhanced by DPP-4 inhibition.</offsets></p><sec id="s1"><title><offsets xml_i="11422" xml_f="11449" txt_i="5176" txt_f="5203">RESEARCH DESIGN AND METHODS</offsets></title><p><offsets xml_i="11460" xml_f="11667" txt_i="5204" txt_f="5411">Twelve patients with type 2 diabetes (9 males and 3 females), managed by diet alone, were studied after they had provided written informed consent. The mean ± SE age was 66.2 ± 1.4 years, BMI 28.9 ± 1.0 kg/m</offsets><sup><offsets xml_i="11672" xml_f="11673" txt_i="5411" txt_f="5412">2</offsets></sup><offsets xml_i="11679" xml_f="11684" txt_i="5412" txt_f="5417">, HbA</offsets><sub><offsets xml_i="11689" xml_f="11691" txt_i="5417" txt_f="5419">1c</offsets></sub><offsets xml_i="11697" xml_f="12101" txt_i="5419" txt_f="5823"> 6.6 ± 0.2% (48.9 ± 2.5 mmol/mol), and duration of known diabetes 4.9 ± 1.1 years. None had significant comorbidities, were smokers, or were taking any medication known to affect gastrointestinal function. The protocol was approved by the human research ethics committee of the Royal Adelaide Hospital and was conducted in accordance with the principles of the Declaration of Helsinki as revised in 2000.</offsets></p><p><offsets xml_i="12108" xml_f="12595" txt_i="5824" txt_f="6307">Each subject was studied on four occasions, separated by at least 3 days, in randomized double-blind fashion. On the evening before each study day (∼1900 h), each subject consumed a standardized evening meal (McCain’s frozen beef lasagna, 2,170 kJ; McCain Foods Proprietary, Victoria, Australia). At ∼2200 h, subjects took a tablet of either 100 mg sitagliptin (Januvia; Merck Sharp &amp; Dohme) or matching placebo, and compliance was reinforced with a reminder phone call that evening.</offsets></p><p><offsets xml_i="12602" xml_f="12873" txt_i="6308" txt_f="6579">Subjects then fasted until the following morning, when they attended the laboratory at ∼0800 h and were seated comfortably for the duration of the study. An intravenous cannula was inserted into an antecubital vein for repeated blood sampling. On each study day, between </offsets><italic><offsets xml_i="12881" xml_f="12882" txt_i="6579" txt_f="6580">t</offsets></italic><offsets xml_i="12891" xml_f="12971" txt_i="6580" txt_f="6660"> = −40 and −38 min, they consumed a 200-mL preload drink containing either 50 g </offsets><sc><offsets xml_i="12975" xml_f="12976" txt_i="6660" txt_f="6661">d</offsets></sc><offsets xml_i="12981" xml_f="13141" txt_i="6661" txt_f="6821">-xylose or 80 mg sucralose (a control of equivalent sweetness, which we have shown not to stimulate GLP-1 secretion or slow gastric emptying in healthy humans [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="13173" xml_f="13175" txt_i="6821" txt_f="6823">21</offsets></xref><offsets xml_i="13182" xml_f="13183" txt_i="6823" txt_f="6824">,</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="13215" xml_f="13217" txt_i="6824" txt_f="6826">22</offsets></xref><offsets xml_i="13224" xml_f="13278" txt_i="6826" txt_f="6880">]), so that the four treatments were sitagliptin plus </offsets><sc><offsets xml_i="13282" xml_f="13283" txt_i="6880" txt_f="6881">d</offsets></sc><offsets xml_i="13288" xml_f="13346" txt_i="6881" txt_f="6939">-xylose (SX), sitagliptin plus control (SC), placebo plus </offsets><sc><offsets xml_i="13350" xml_f="13351" txt_i="6939" txt_f="6940">d</offsets></sc><offsets xml_i="13356" xml_f="13430" txt_i="6940" txt_f="7014">-xylose (PX), and placebo plus control (PC). Forty minutes later (between </offsets><italic><offsets xml_i="13438" xml_f="13439" txt_i="7014" txt_f="7015">t</offsets></italic><offsets xml_i="13448" xml_f="13665" txt_i="7015" txt_f="7232"> = 0 and 5 min), they ate a solid meal consisting of 65 g powdered potato (Deb Instant Mashed Potato; Continental, Epping, Australia) and 20 g glucose, reconstituted with 200 mL water and 1 egg yolk containing 100 μL </offsets><sup><offsets xml_i="13670" xml_f="13672" txt_i="7232" txt_f="7234">13</offsets></sup><offsets xml_i="13678" xml_f="13955" txt_i="7234" txt_f="7511">C-octanoic acid. Breath samples were collected immediately before and every 5 min after meal ingestion in the first hour and every 15 min for a further 3 h for the measurement of gastric emptying. Venous blood samples and additional breath samples before the preload drink (at </offsets><italic><offsets xml_i="13963" xml_f="13964" txt_i="7511" txt_f="7512">t</offsets></italic><offsets xml_i="13973" xml_f="13992" txt_i="7512" txt_f="7531"> = −40 min) and at </offsets><italic><offsets xml_i="14000" xml_f="14001" txt_i="7531" txt_f="7532">t</offsets></italic><offsets xml_i="14010" xml_f="14147" txt_i="7532" txt_f="7669"> = −20, 0, 15, 30, 60, 90, 120, and 240 min were taken for the measurements of blood glucose, insulin, intact GLP-1, and breath hydrogen.</offsets></p><p><offsets xml_i="14154" xml_f="14617" txt_i="7670" txt_f="8133">Blood samples for insulin were collected in serum tubes. For the measurement of intact GLP-1, venous blood was collected into ice-chilled EDTA tubes containing DPP-4 inhibitor (DPP4-010; Linco Research, St. Charles, MO) (10 μL/mL blood). Samples were mixed six times by gentle inversion and stored on ice before centrifugation at 3,200 rpm for 15 min at 4°C within 15 min of collection. Serum and plasma were separated and stored at –70°C for subsequent analysis.</offsets></p><sec id="s2"><title><offsets xml_i="14641" xml_f="14687" txt_i="8134" txt_f="8180">Blood glucose, serum insulin, and intact GLP-1</offsets></title><p><offsets xml_i="14698" xml_f="14913" txt_i="8181" txt_f="8396">Blood glucose concentrations were measured immediately using a glucometer (Medisense Precision QID; Abbott Laboratories, Bedford, MA). The accuracy of the method has been validated against the hexokinase technique (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="14944" xml_f="14945" txt_i="8396" txt_f="8397">4</offsets></xref><offsets xml_i="14952" xml_f="14954" txt_i="8397" txt_f="8399">).</offsets></p><p><offsets xml_i="14961" xml_f="15178" txt_i="8400" txt_f="8617">Serum insulin was measured by ELISA immunoassay (cat. no. 10-1113; Mercodia, Uppsala, Sweden). The sensitivity of the assay was 1.0 mU/L and the coefficient of variation was 2.1% within assays and 6.6% between assays.</offsets></p><p><offsets xml_i="15185" xml_f="15559" txt_i="8618" txt_f="8992">Plasma intact GLP-1 was measured by radioimmunoassay using a commercially available kit (GLP1A-35HK; Millipore, Billerica, MA), which allows quantification of biologically active forms of GLP-1 (i.e., 7-36 amide and 7-37) in plasma and other biological media. The sensitivity was 3 pmol/L, and intra- and interassay coefficients of variation were 3.4 and 9.1%, respectively.</offsets></p></sec><sec id="s3"><title><offsets xml_i="15589" xml_f="15605" txt_i="8994" txt_f="9010">Gastric emptying</offsets></title><p><sup><offsets xml_i="15621" xml_f="15623" txt_i="9011" txt_f="9013">13</offsets></sup><offsets xml_i="15629" xml_f="15631" txt_i="9013" txt_f="9015">CO</offsets><sub><offsets xml_i="15636" xml_f="15637" txt_i="9015" txt_f="9016">2</offsets></sub><offsets xml_i="15643" xml_f="15919" txt_i="9016" txt_f="9292"> concentrations in breath samples were measured by an isotope ratio mass spectrometer (ABCA 2020; Europa Scientific, Crewe, U.K.) with an online gas chromatographic purification system. The half-emptying time (T50) was calculated, using the formula described by Ghoos et al. (</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="15951" xml_f="15953" txt_i="9292" txt_f="9294">23</offsets></xref><offsets xml_i="15960" xml_f="16056" txt_i="9294" txt_f="9390">). This method has been validated against scintigraphy for the measurement of gastric emptying (</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="16088" xml_f="16090" txt_i="9390" txt_f="9392">24</offsets></xref><offsets xml_i="16097" xml_f="16099" txt_i="9392" txt_f="9394">).</offsets></p></sec><sec id="s4"><title><offsets xml_i="16129" xml_f="16144" txt_i="9396" txt_f="9411">Breath hydrogen</offsets></title><p><offsets xml_i="16155" xml_f="16302" txt_i="9412" txt_f="9559">Hydrogen concentrations in breath samples were measured using Quintron MicroLyzer SC (Quintron Instrument, Milwaukee, WI) and were corrected for CO</offsets><sub><offsets xml_i="16307" xml_f="16308" txt_i="9559" txt_f="9560">2</offsets></sub><offsets xml_i="16314" xml_f="16323" txt_i="9560" txt_f="9569"> levels (</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="16355" xml_f="16357" txt_i="9569" txt_f="9571">25</offsets></xref><offsets xml_i="16364" xml_f="16366" txt_i="9571" txt_f="9573">).</offsets></p></sec><sec id="s5"><title><offsets xml_i="16396" xml_f="16416" txt_i="9575" txt_f="9595">Statistical analysis</offsets></title><p><offsets xml_i="16427" xml_f="16517" txt_i="9596" txt_f="9686">The incremental areas under the curve (iAUCs) were calculated using the trapezoidal rule (</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="16549" xml_f="16551" txt_i="9686" txt_f="9688">26</offsets></xref><offsets xml_i="16558" xml_f="16880" txt_i="9688" txt_f="10010">) for blood glucose, serum insulin, plasma intact GLP-1, and breath hydrogen and analyzed using one-factor repeated-measures ANOVA. These variables were also assessed by repeated-measures ANOVA, with treatment and time as factors. The amplitude of glycemic excursion (AGE) (postprandial glycemic peak minus the nadir) and </offsets><italic><offsets xml_i="16888" xml_f="16889" txt_i="10010" txt_f="10011">J</offsets></italic><offsets xml_i="16898" xml_f="16906" txt_i="10011" txt_f="10019"> index [</offsets><italic><offsets xml_i="16914" xml_f="16915" txt_i="10019" txt_f="10020">J</offsets></italic><offsets xml_i="16924" xml_f="16960" txt_i="10020" txt_f="10056"> = 0.324 × (mean blood glucose + SD)</offsets><sup><offsets xml_i="16965" xml_f="16966" txt_i="10056" txt_f="10057">2</offsets></sup><offsets xml_i="16972" xml_f="17052" txt_i="10057" txt_f="10137">] were calculated as measures of glycemic variability, as previously described (</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="17084" xml_f="17086" txt_i="10137" txt_f="10139">27</offsets></xref><offsets xml_i="17093" xml_f="17517" txt_i="10139" txt_f="10563">), and these together with gastric emptying (T50) were compared using one-factor ANOVA. Post hoc comparisons, adjusted for multiple comparisons by Bonferroni-Holm correction, were performed if ANOVAs showed significant effects. Relationships between variables were assessed using linear regression analysis. All analyses were performed with SPSS Statistics (version 19.0; IBM, Armonk, NY). Data are presented as means ± SE; </offsets><italic><offsets xml_i="17525" xml_f="17526" txt_i="10563" txt_f="10564">P</offsets></italic><offsets xml_i="17535" xml_f="17587" txt_i="10564" txt_f="10613"> &lt; 0.05 was considered statistically significant.</offsets></p></sec></sec><sec sec-type="results" id="s6"><title><offsets xml_i="17642" xml_f="17649" txt_i="10616" txt_f="10623">RESULTS</offsets></title><p><offsets xml_i="17660" xml_f="17788" txt_i="10624" txt_f="10752">All subjects tolerated the study well. Three subjects reported mild transient loose stools after completion of the study on the </offsets><sc><offsets xml_i="17792" xml_f="17793" txt_i="10752" txt_f="10753">d</offsets></sc><offsets xml_i="17798" xml_f="17811" txt_i="10753" txt_f="10766">-xylose days.</offsets></p><sec id="s7"><title><offsets xml_i="17835" xml_f="17863" txt_i="10767" txt_f="10795">Blood glucose concentrations</offsets></title><p><offsets xml_i="17874" xml_f="18118" txt_i="10796" txt_f="11040">Fasting blood glucose concentrations did not differ between the four study days (PC 7.4 ± 0.3 mmol/L, PX 7.5 ± 0.3 mmol/L, SC 7.1 ± 0.3 mmol/L, and SX 7.5 ± 0.4 mmol/L). Before the meal, blood glucose concentrations increased slightly when the </offsets><sc><offsets xml_i="18122" xml_f="18123" txt_i="11040" txt_f="11041">d</offsets></sc><offsets xml_i="18128" xml_f="18283" txt_i="11041" txt_f="11196">-xylose preload was given (i.e., PX and SX) in contrast to the control days, so that the iAUC (−40 to 0 min) was greater for PX and SX than for PC and SC (</offsets><italic><offsets xml_i="18291" xml_f="18292" txt_i="11196" txt_f="11197">P</offsets></italic><offsets xml_i="18301" xml_f="18323" txt_i="11197" txt_f="11216"> &lt; 0.05 for each) (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="18355" xml_f="18362" txt_i="11216" txt_f="11223">Table 1</offsets></xref><offsets xml_i="18369" xml_f="18510" txt_i="11223" txt_f="11364">). After the meal, blood glucose concentrations increased on each day before returning to baseline. The postprandial glycemic peak, AGE, and </offsets><italic><offsets xml_i="18518" xml_f="18519" txt_i="11364" txt_f="11365">J</offsets></italic><offsets xml_i="18528" xml_f="18575" txt_i="11365" txt_f="11412"> index were all lower after PX and SC than PC (</offsets><italic><offsets xml_i="18583" xml_f="18584" txt_i="11412" txt_f="11413">P</offsets></italic><offsets xml_i="18593" xml_f="18640" txt_i="11413" txt_f="11457"> &lt; 0.01 for each) and were lowest after SX (</offsets><italic><offsets xml_i="18648" xml_f="18649" txt_i="11457" txt_f="11458">P</offsets></italic><offsets xml_i="18658" xml_f="18680" txt_i="11458" txt_f="11477"> &lt; 0.05 for each) (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="18712" xml_f="18719" txt_i="11477" txt_f="11484">Table 1</offsets></xref><offsets xml_i="18726" xml_f="18809" txt_i="11484" txt_f="11567">). There was a significant treatment effect on the overall iAUC for blood glucose (</offsets><italic><offsets xml_i="18817" xml_f="18818" txt_i="11567" txt_f="11568">P</offsets></italic><offsets xml_i="18827" xml_f="18838" txt_i="11568" txt_f="11579"> = 0.008) (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="18870" xml_f="18877" txt_i="11579" txt_f="11586">Table 1</offsets></xref><offsets xml_i="18884" xml_f="18948" txt_i="11586" txt_f="11650">), such that blood glucose was lower after SX compared with PC (</offsets><italic><offsets xml_i="18956" xml_f="18957" txt_i="11650" txt_f="11651">P</offsets></italic><offsets xml_i="18966" xml_f="18979" txt_i="11651" txt_f="11661"> &lt; 0.05) (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="19009" xml_f="19015" txt_i="11661" txt_f="11667">Fig. 1</offsets><italic><offsets xml_i="19023" xml_f="19024" txt_i="11667" txt_f="11668">A</offsets></italic></xref><offsets xml_i="19040" xml_f="19042" txt_i="11668" txt_f="11670">).</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="19090" xml_f="19097" txt_i="11671" txt_f="11678">Table 1</offsets></label><caption><p><offsets xml_i="19117" xml_f="19145" txt_i="11678" txt_f="11706">Postprandial glycemic peak, </offsets><italic><offsets xml_i="19153" xml_f="19154" txt_i="11706" txt_f="11707">J</offsets></italic><offsets xml_i="19163" xml_f="19286" txt_i="11707" txt_f="11830"> index, AGE, iAUC for blood glucose, serum insulin, and GLP-1 in response to a carbohydrate meal after a preload of either </offsets><sc><offsets xml_i="19290" xml_f="19291" txt_i="11830" txt_f="11831">d</offsets></sc><offsets xml_i="19296" xml_f="19363" txt_i="11831" txt_f="11898">-xylose or sucralose (control) with or without 100 mg sitagliptin (</offsets><italic><offsets xml_i="19371" xml_f="19372" txt_i="11898" txt_f="11899">n</offsets></italic><offsets xml_i="19381" xml_f="19387" txt_i="11899" txt_f="11905"> = 12)</offsets></p></caption><graphic xlink:href="1913tbl1"></graphic></table-wrap><fig id="F1" fig-type="figure" position="float"><label><offsets xml_i="19510" xml_f="19518" txt_i="11906" txt_f="11914">Figure 1</offsets></label><caption><p><offsets xml_i="19538" xml_f="19549" txt_i="11914" txt_f="11925">Effects of </offsets><sc><offsets xml_i="19553" xml_f="19554" txt_i="11925" txt_f="11926">d</offsets></sc><offsets xml_i="19559" xml_f="19636" txt_i="11926" txt_f="12003">-xylose or sucralose (control) with or without sitagliptin on blood glucose (</offsets><italic><offsets xml_i="19644" xml_f="19645" txt_i="12003" txt_f="12004">A</offsets></italic><offsets xml_i="19654" xml_f="19672" txt_i="12004" txt_f="12022">), serum insulin (</offsets><italic><offsets xml_i="19680" xml_f="19681" txt_i="12022" txt_f="12023">B</offsets></italic><offsets xml_i="19690" xml_f="19719" txt_i="12023" txt_f="12052">), insulin-to-glucose ratio (</offsets><italic><offsets xml_i="19727" xml_f="19728" txt_i="12052" txt_f="12053">C</offsets></italic><offsets xml_i="19737" xml_f="19765" txt_i="12053" txt_f="12081">), and plasma intact GLP-1 (</offsets><italic><offsets xml_i="19773" xml_f="19774" txt_i="12081" txt_f="12082">D</offsets></italic><offsets xml_i="19783" xml_f="19821" txt_i="12082" txt_f="12120">) in response to a carbohydrate meal (</offsets><italic><offsets xml_i="19829" xml_f="19830" txt_i="12120" txt_f="12121">n</offsets></italic><offsets xml_i="19839" xml_f="20028" txt_i="12121" txt_f="12310"> = 12). The four treatments were SX, SC, PX, and PC. Repeated-measures ANOVA was used to determine statistical difference. Post hoc comparisons were adjusted by Bonferroni-Holm correction. </offsets><italic><offsets xml_i="20036" xml_f="20037" txt_i="12310" txt_f="12311">P</offsets></italic><offsets xml_i="20046" xml_f="20095" txt_i="12311" txt_f="12360"> = 0.000 for each treatment × time interaction; *</offsets><italic><offsets xml_i="20103" xml_f="20104" txt_i="12360" txt_f="12361">P</offsets></italic><offsets xml_i="20113" xml_f="20137" txt_i="12361" txt_f="12382"> &lt; 0.05, PX vs. PC; #</offsets><italic><offsets xml_i="20145" xml_f="20146" txt_i="12382" txt_f="12383">P</offsets></italic><offsets xml_i="20155" xml_f="20179" txt_i="12383" txt_f="12404"> &lt; 0.05, SC vs. PC; α</offsets><italic><offsets xml_i="20187" xml_f="20188" txt_i="12404" txt_f="12405">P</offsets></italic><offsets xml_i="20197" xml_f="20221" txt_i="12405" txt_f="12426"> &lt; 0.05, SX vs. PC; δ</offsets><italic><offsets xml_i="20229" xml_f="20230" txt_i="12426" txt_f="12427">P</offsets></italic><offsets xml_i="20239" xml_f="20263" txt_i="12427" txt_f="12448"> &lt; 0.05, SX vs. PX; ε</offsets><italic><offsets xml_i="20271" xml_f="20272" txt_i="12448" txt_f="12449">P</offsets></italic><offsets xml_i="20281" xml_f="20325" txt_i="12449" txt_f="12490"> &lt; 0.05, SX vs. SC. Data are means ± SEM.</offsets></p></caption><graphic xlink:href="1913fig1"></graphic></fig></sec><sec id="s8"><title><offsets xml_i="20412" xml_f="20425" txt_i="12492" txt_f="12505">Serum insulin</offsets></title><p><offsets xml_i="20436" xml_f="20581" txt_i="12506" txt_f="12651">Fasting serum insulin concentrations did not differ between the four study days. Before the meal, insulin concentrations increased slightly when </offsets><sc><offsets xml_i="20585" xml_f="20586" txt_i="12651" txt_f="12652">d</offsets></sc><offsets xml_i="20591" xml_f="20738" txt_i="12652" txt_f="12799">-xylose was given (i.e., PX and SX) in contrast to the control days, so that the iAUC (−40 to 0 min) was greater for PX and SX than for PC and SC (</offsets><italic><offsets xml_i="20746" xml_f="20747" txt_i="12799" txt_f="12800">P</offsets></italic><offsets xml_i="20756" xml_f="20778" txt_i="12800" txt_f="12819"> &lt; 0.05 for each) (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="20810" xml_f="20817" txt_i="12819" txt_f="12826">Table 1</offsets></xref><offsets xml_i="20824" xml_f="20899" txt_i="12826" txt_f="12901">). After the meal, serum insulin concentrations increased on each day, but </offsets><sc><offsets xml_i="20903" xml_f="20904" txt_i="12901" txt_f="12902">d</offsets></sc><offsets xml_i="20909" xml_f="21014" txt_i="12902" txt_f="13007">-xylose and sitagliptin alone and in combination resulted in a lower postprandial serum insulin than PC (</offsets><italic><offsets xml_i="21022" xml_f="21023" txt_i="13007" txt_f="13008">P</offsets></italic><offsets xml_i="21032" xml_f="21107" txt_i="13008" txt_f="13083"> = 0.000 for treatment × time interaction, with significant differences at </offsets><italic><offsets xml_i="21115" xml_f="21116" txt_i="13083" txt_f="13084">t</offsets></italic><offsets xml_i="21125" xml_f="21176" txt_i="13084" txt_f="13135"> = 30, 60, and 90 min for PX vs. PC and SX vs. PC; </offsets><italic><offsets xml_i="21184" xml_f="21185" txt_i="13135" txt_f="13136">t</offsets></italic><offsets xml_i="21194" xml_f="21223" txt_i="13136" txt_f="13165"> = 90 min for SC vs. PC; and </offsets><italic><offsets xml_i="21231" xml_f="21232" txt_i="13165" txt_f="13166">t</offsets></italic><offsets xml_i="21241" xml_f="21266" txt_i="13166" txt_f="13191"> = 30 min for SX vs. SC [</offsets><italic><offsets xml_i="21274" xml_f="21275" txt_i="13191" txt_f="13192">P</offsets></italic><offsets xml_i="21284" xml_f="21392" txt_i="13192" txt_f="13297"> &lt; 0.05 for each]). There was also a significant treatment effect on the overall iAUC for serum insulin (</offsets><italic><offsets xml_i="21400" xml_f="21401" txt_i="13297" txt_f="13298">P</offsets></italic><offsets xml_i="21410" xml_f="21421" txt_i="13298" txt_f="13309"> = 0.009) (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="21453" xml_f="21460" txt_i="13309" txt_f="13316">Table 1</offsets></xref><offsets xml_i="21467" xml_f="21532" txt_i="13316" txt_f="13381">), such that insulin concentrations were lower after SX than PC (</offsets><italic><offsets xml_i="21540" xml_f="21541" txt_i="13381" txt_f="13382">P</offsets></italic><offsets xml_i="21550" xml_f="21563" txt_i="13382" txt_f="13392"> &lt; 0.05) (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="21593" xml_f="21599" txt_i="13392" txt_f="13398">Fig. 1</offsets><italic><offsets xml_i="21607" xml_f="21608" txt_i="13398" txt_f="13399">B</offsets></italic></xref><offsets xml_i="21624" xml_f="21626" txt_i="13399" txt_f="13401">).</offsets></p><p><offsets xml_i="21633" xml_f="21680" txt_i="13402" txt_f="13449">Before the meal, the insulin-to-glucose ratio (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="21710" xml_f="21716" txt_i="13449" txt_f="13455">Fig. 1</offsets><italic><offsets xml_i="21724" xml_f="21725" txt_i="13455" txt_f="13456">C</offsets></italic></xref><offsets xml_i="21741" xml_f="21773" txt_i="13456" txt_f="13488">) remained unchanged after both </offsets><sc><offsets xml_i="21777" xml_f="21778" txt_i="13488" txt_f="13489">d</offsets></sc><offsets xml_i="21783" xml_f="21871" txt_i="13489" txt_f="13577">-xylose and control preloads, but the ratio increased after the meal and was lower from </offsets><italic><offsets xml_i="21879" xml_f="21880" txt_i="13577" txt_f="13578">t</offsets></italic><offsets xml_i="21889" xml_f="21915" txt_i="13578" txt_f="13604"> = 30 to 90 min after the </offsets><sc><offsets xml_i="21919" xml_f="21920" txt_i="13604" txt_f="13605">d</offsets></sc><offsets xml_i="21925" xml_f="21964" txt_i="13605" txt_f="13644">-xylose preload compared with control (</offsets><italic><offsets xml_i="21972" xml_f="21973" txt_i="13644" txt_f="13645">P</offsets></italic><offsets xml_i="21982" xml_f="22052" txt_i="13645" txt_f="13715"> = 0.000 for a treatment × time interaction: PX vs. PC and SX vs. SC [</offsets><italic><offsets xml_i="22060" xml_f="22061" txt_i="13715" txt_f="13716">P</offsets></italic><offsets xml_i="22070" xml_f="22126" txt_i="13716" txt_f="13769"> &lt; 0.05 for each]) without any effect of sitagliptin.</offsets></p></sec><sec id="s9"><title><offsets xml_i="22156" xml_f="22175" txt_i="13771" txt_f="13790">Plasma intact GLP-1</offsets></title><p><offsets xml_i="22186" xml_f="22330" txt_i="13791" txt_f="13935">Fasting plasma intact GLP-1 concentrations did not differ between the four study days. Before the meal, GLP-1 concentrations increased when the </offsets><sc><offsets xml_i="22334" xml_f="22335" txt_i="13935" txt_f="13936">d</offsets></sc><offsets xml_i="22340" xml_f="22434" txt_i="13936" txt_f="14030">-xylose preload was given, so that the iAUC (−40 to 0) was greater for SX than for PC and SC (</offsets><italic><offsets xml_i="22442" xml_f="22443" txt_i="14030" txt_f="14031">P</offsets></italic><offsets xml_i="22452" xml_f="22474" txt_i="14031" txt_f="14050"> &lt; 0.05 for each) (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="22506" xml_f="22513" txt_i="14050" txt_f="14057">Table 1</offsets></xref><offsets xml_i="22520" xml_f="22673" txt_i="14057" txt_f="14210">), although the difference between PX and PC was not significant. After the meal, intact GLP-1 increased on the control days, but the combination of the </offsets><sc><offsets xml_i="22677" xml_f="22678" txt_i="14210" txt_f="14211">d</offsets></sc><offsets xml_i="22683" xml_f="22800" txt_i="14211" txt_f="14328">-xylose preload with sitagliptin resulted in more sustained elevation of plasma intact GLP-1 than on the other days (</offsets><italic><offsets xml_i="22808" xml_f="22809" txt_i="14328" txt_f="14329">P</offsets></italic><offsets xml_i="22818" xml_f="22895" txt_i="14329" txt_f="14406"> = 0.000 for a treatment × time interaction, with significant differences at </offsets><italic><offsets xml_i="22903" xml_f="22904" txt_i="14406" txt_f="14407">t</offsets></italic><offsets xml_i="22913" xml_f="22965" txt_i="14407" txt_f="14459"> = 15, 60, 90, and 120 min for SX vs. PC and during </offsets><italic><offsets xml_i="22973" xml_f="22974" txt_i="14459" txt_f="14460">t</offsets></italic><offsets xml_i="22983" xml_f="23008" txt_i="14460" txt_f="14485"> = 30–120 for SX vs. PX [</offsets><italic><offsets xml_i="23016" xml_f="23017" txt_i="14485" txt_f="14486">P</offsets></italic><offsets xml_i="23026" xml_f="23128" txt_i="14486" txt_f="14585"> &lt; 0.05 for each]). There was also a treatment effect on the overall iAUC for plasma intact GLP-1 (</offsets><italic><offsets xml_i="23136" xml_f="23137" txt_i="14585" txt_f="14586">P</offsets></italic><offsets xml_i="23146" xml_f="23157" txt_i="14586" txt_f="14597"> = 0.003) (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="23189" xml_f="23196" txt_i="14597" txt_f="14604">Table 1</offsets></xref><offsets xml_i="23203" xml_f="23268" txt_i="14604" txt_f="14669">), such that GLP-1 was greatest after SX (SX vs. PC, PX, and SC, </offsets><italic><offsets xml_i="23276" xml_f="23277" txt_i="14669" txt_f="14670">P</offsets></italic><offsets xml_i="23286" xml_f="23308" txt_i="14670" txt_f="14689"> &lt; 0.05 for each) (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="23338" xml_f="23344" txt_i="14689" txt_f="14695">Fig. 1</offsets><italic><offsets xml_i="23352" xml_f="23353" txt_i="14695" txt_f="14696">D</offsets></italic></xref><offsets xml_i="23369" xml_f="23371" txt_i="14696" txt_f="14698">).</offsets></p></sec><sec id="s10"><title><offsets xml_i="23402" xml_f="23428" txt_i="14700" txt_f="14726">Breath hydrogen production</offsets></title><p><offsets xml_i="23439" xml_f="23540" txt_i="14727" txt_f="14828">Fasting breath hydrogen approximated 0 ppm and did not differ between the four study days. After the </offsets><sc><offsets xml_i="23544" xml_f="23545" txt_i="14828" txt_f="14829">d</offsets></sc><offsets xml_i="23550" xml_f="23617" txt_i="14829" txt_f="14896">-xylose drink, breath hydrogen increased slightly before the meal (</offsets><italic><offsets xml_i="23625" xml_f="23626" txt_i="14896" txt_f="14897">t</offsets></italic><offsets xml_i="23635" xml_f="23787" txt_i="14897" txt_f="15049"> = −40 to 0 min) and continued to rise to a plateau afterward, while it remained unchanged after the control preload and was unaffected by sitagliptin (</offsets><italic><offsets xml_i="23795" xml_f="23796" txt_i="15049" txt_f="15050">P</offsets></italic><offsets xml_i="23805" xml_f="23851" txt_i="15050" txt_f="15096"> = 0.000 for a treatment × time interaction) (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="23881" xml_f="23887" txt_i="15096" txt_f="15102">Fig. 2</offsets></xref><offsets xml_i="23894" xml_f="23896" txt_i="15102" txt_f="15104">).</offsets></p><fig id="F2" fig-type="figure" position="float"><label><offsets xml_i="23955" xml_f="23963" txt_i="15105" txt_f="15113">Figure 2</offsets></label><caption><p><offsets xml_i="23983" xml_f="23994" txt_i="15113" txt_f="15124">Effects of </offsets><sc><offsets xml_i="23998" xml_f="23999" txt_i="15124" txt_f="15125">d</offsets></sc><offsets xml_i="24004" xml_f="24129" txt_i="15125" txt_f="15250">-xylose or sucralose (control) with or without sitagliptin on breath hydrogen production in response to a carbohydrate meal (</offsets><italic><offsets xml_i="24137" xml_f="24138" txt_i="15250" txt_f="15251">n</offsets></italic><offsets xml_i="24147" xml_f="24286" txt_i="15251" txt_f="15390"> = 12). The four treatments were SX (■), SC (●), PX (), and PC (○). Repeated-measures ANOVA was used to determine statistical difference. *</offsets><italic><offsets xml_i="24294" xml_f="24295" txt_i="15390" txt_f="15391">P</offsets></italic><offsets xml_i="24304" xml_f="24333" txt_i="15391" txt_f="15420"> = 0.000, PX vs. PC and SC; #</offsets><italic><offsets xml_i="24341" xml_f="24342" txt_i="15420" txt_f="15421">P</offsets></italic><offsets xml_i="24351" xml_f="24400" txt_i="15421" txt_f="15470"> = 0.000, SX vs. PC and SC. Data are means ± SEM.</offsets></p></caption><graphic xlink:href="1913fig2"></graphic></fig></sec><sec id="s11"><title><offsets xml_i="24488" xml_f="24504" txt_i="15472" txt_f="15488">Gastric emptying</offsets></title><p><offsets xml_i="24515" xml_f="24566" txt_i="15489" txt_f="15540">There was a treatment effect for gastric emptying (</offsets><italic><offsets xml_i="24574" xml_f="24575" txt_i="15540" txt_f="15541">P</offsets></italic><offsets xml_i="24584" xml_f="24646" txt_i="15541" txt_f="15603"> = 0.000), such that the half-emptying time was greater after </offsets><sc><offsets xml_i="24650" xml_f="24651" txt_i="15603" txt_f="15604">d</offsets></sc><offsets xml_i="24656" xml_f="24777" txt_i="15604" txt_f="15725">-xylose than control (T50 for PX 238.2 ± 26.4 min and SX 256.9 ± 23.1 min vs. PC 152.3 ± 6.0 min and SC166.3 ± 11.0 min [</offsets><italic><offsets xml_i="24785" xml_f="24786" txt_i="15725" txt_f="15726">P</offsets></italic><offsets xml_i="24795" xml_f="24852" txt_i="15726" txt_f="15780"> &lt; 0.01 for each]) without any effect of sitagliptin (</offsets><xref ref-type="fig" rid="F3"><offsets xml_i="24882" xml_f="24888" txt_i="15780" txt_f="15786">Fig. 3</offsets></xref><offsets xml_i="24895" xml_f="24897" txt_i="15786" txt_f="15788">).</offsets></p><fig id="F3" fig-type="figure" position="float"><label><offsets xml_i="24956" xml_f="24964" txt_i="15789" txt_f="15797">Figure 3</offsets></label><caption><p><offsets xml_i="24984" xml_f="24995" txt_i="15797" txt_f="15808">Effects of </offsets><sc><offsets xml_i="24999" xml_f="25000" txt_i="15808" txt_f="15809">d</offsets></sc><offsets xml_i="25005" xml_f="25112" txt_i="15809" txt_f="15916">-xylose or sucralose (control) with or without sitagliptin on gastric emptying (half-emptying time [T50]) (</offsets><italic><offsets xml_i="25120" xml_f="25121" txt_i="15916" txt_f="15917">n</offsets></italic><offsets xml_i="25130" xml_f="25330" txt_i="15917" txt_f="16117"> = 12). The four treatments were SX, SC, PX, and PC. One-factor repeated-measures ANOVA was used to determine statistical difference. Post hoc comparisons were adjusted by Bonferroni-Holm correction. </offsets><italic><offsets xml_i="25338" xml_f="25339" txt_i="16117" txt_f="16118">P</offsets></italic><offsets xml_i="25348" xml_f="25382" txt_i="16118" txt_f="16152"> = 0.000 for a treatment effect; *</offsets><italic><offsets xml_i="25390" xml_f="25391" txt_i="16152" txt_f="16153">P</offsets></italic><offsets xml_i="25400" xml_f="25431" txt_i="16153" txt_f="16181"> &lt; 0.01, PX vs. PC and SC; #</offsets><italic><offsets xml_i="25439" xml_f="25440" txt_i="16181" txt_f="16182">P</offsets></italic><offsets xml_i="25449" xml_f="25501" txt_i="16182" txt_f="16231"> &lt; 0.001, SX vs. PC and SC. Data are means ± SEM.</offsets></p></caption><graphic xlink:href="1913fig3"></graphic></fig></sec><sec id="s12"><title><offsets xml_i="25589" xml_f="25698" txt_i="16233" txt_f="16342">Relationships between blood glucose and gastric emptying, plasma intact GLP-1, and breath hydrogen production</offsets></title><p><offsets xml_i="25709" xml_f="25832" txt_i="16343" txt_f="16466">When data from the four study visits were pooled, the magnitude of the postprandial rise in blood glucose from baseline at </offsets><italic><offsets xml_i="25840" xml_f="25841" txt_i="16466" txt_f="16467">t</offsets></italic><offsets xml_i="25850" xml_f="25906" txt_i="16467" txt_f="16523"> = 30, 60, and 90 min was inversely related to the T50 (</offsets><italic><offsets xml_i="25914" xml_f="25915" txt_i="16523" txt_f="16524">P</offsets></italic><offsets xml_i="25924" xml_f="25952" txt_i="16524" txt_f="16549"> &lt; 0.01 for each) and at </offsets><italic><offsets xml_i="25960" xml_f="25961" txt_i="16549" txt_f="16550">t</offsets></italic><offsets xml_i="25970" xml_f="26010" txt_i="16550" txt_f="16590"> = 240 min directly related to the T50 (</offsets><italic><offsets xml_i="26018" xml_f="26019" txt_i="16590" txt_f="16591">P</offsets></italic><offsets xml_i="26028" xml_f="26038" txt_i="16591" txt_f="16601"> = 0.001).</offsets></p><p><offsets xml_i="26045" xml_f="26375" txt_i="16602" txt_f="16932">Given that plasma intact GLP-1 would be more sensitive as a measure of GLP-1 secretion when DPP-4 was inhibited, data from the SX day alone were examined for a relationship between breath hydrogen production and GLP-1 secretion. Intact GLP-1 concentrations were found to be related directly to breath hydrogen production (for iAUC</offsets><sub><offsets xml_i="26380" xml_f="26388" txt_i="16932" txt_f="16940">−40 to 0</offsets></sub><offsets xml_i="26394" xml_f="26396" txt_i="16940" txt_f="16942">, </offsets><italic><offsets xml_i="26404" xml_f="26405" txt_i="16942" txt_f="16943">r</offsets></italic><offsets xml_i="26414" xml_f="26423" txt_i="16943" txt_f="16952"> = 0.72, </offsets><italic><offsets xml_i="26431" xml_f="26432" txt_i="16952" txt_f="16953">P</offsets></italic><offsets xml_i="26441" xml_f="26459" txt_i="16953" txt_f="16971"> = 0.009; for iAUC</offsets><sub><offsets xml_i="26464" xml_f="26474" txt_i="16971" txt_f="16981">−40 to 240</offsets></sub><offsets xml_i="26480" xml_f="26482" txt_i="16981" txt_f="16983">, </offsets><italic><offsets xml_i="26490" xml_f="26491" txt_i="16983" txt_f="16984">r</offsets></italic><offsets xml_i="26500" xml_f="26509" txt_i="16984" txt_f="16993"> = 0.74, </offsets><italic><offsets xml_i="26517" xml_f="26518" txt_i="16993" txt_f="16994">P</offsets></italic><offsets xml_i="26527" xml_f="26537" txt_i="16994" txt_f="17004"> = 0.006).</offsets></p></sec></sec><sec sec-type="conclusions" id="s13"><title><offsets xml_i="26597" xml_f="26608" txt_i="17007" txt_f="17018">CONCLUSIONS</offsets></title><p><offsets xml_i="26619" xml_f="26719" txt_i="17019" txt_f="17119">The main observations made in this study of patients with type 2 diabetes managed by diet were that </offsets><italic><offsets xml_i="26727" xml_f="26728" txt_i="17119" txt_f="17120">1</offsets></italic><offsets xml_i="26737" xml_f="26777" txt_i="17120" txt_f="17160">) consumption of the low-energy pentose </offsets><sc><offsets xml_i="26781" xml_f="26782" txt_i="17160" txt_f="17161">d</offsets></sc><offsets xml_i="26787" xml_f="26981" txt_i="17161" txt_f="17355">-xylose in advance of a high-carbohydrate meal attenuates the postprandial glycemic excursion in association with stimulation of GLP-1 secretion before the meal and slowing of gastric emptying, </offsets><italic><offsets xml_i="26989" xml_f="26990" txt_i="17355" txt_f="17356">2</offsets></italic><offsets xml_i="26999" xml_f="27219" txt_i="17356" txt_f="17576">) a single dose of the DPP-4 inhibitor sitagliptin increases postprandial intact GLP-1 concentrations and reduces postprandial glycemia without slowing gastric emptying or stimulating postprandial insulin secretion, and </offsets><italic><offsets xml_i="27227" xml_f="27228" txt_i="17576" txt_f="17577">3</offsets></italic><offsets xml_i="27237" xml_f="27260" txt_i="17577" txt_f="17600">) the combination of a </offsets><sc><offsets xml_i="27264" xml_f="27265" txt_i="17600" txt_f="17601">d</offsets></sc><offsets xml_i="27270" xml_f="27473" txt_i="17601" txt_f="17804">-xylose preload with sitagliptin reduces the postprandial glycemic excursion more than either treatment alone. The magnitude of the reduction in postprandial blood glucose achieved by the combination of </offsets><sc><offsets xml_i="27477" xml_f="27478" txt_i="17804" txt_f="17805">d</offsets></sc><offsets xml_i="27483" xml_f="27827" txt_i="17805" txt_f="18149">-xylose preload and sitagliptin in our group of patients with well-controlled type 2 diabetes was substantial (i.e., reduction in peak blood glucose of ∼2.5 mmol/L), and moreover, there was a marked reduction in indices of glycemic variability; the latter is associated with oxidative stress and may independently increase cardiovascular risk (</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="27859" xml_f="27861" txt_i="18149" txt_f="18151">27</offsets></xref><offsets xml_i="27868" xml_f="27870" txt_i="18151" txt_f="18153">).</offsets></p><p><offsets xml_i="27877" xml_f="27886" txt_i="18154" txt_f="18163">We chose </offsets><sc><offsets xml_i="27890" xml_f="27891" txt_i="18163" txt_f="18164">d</offsets></sc><offsets xml_i="27896" xml_f="27978" txt_i="18164" txt_f="18246">-xylose as the preload, since it is incompletely absorbed and poorly metabolized (</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="28010" xml_f="28012" txt_i="18246" txt_f="18248">16</offsets></xref><offsets xml_i="28019" xml_f="28114" txt_i="18248" txt_f="18343">) and, accordingly, additional energy intake is minimized in contrast to preloads such as fat (</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="28146" xml_f="28148" txt_i="18343" txt_f="18345">12</offsets></xref><offsets xml_i="28155" xml_f="28170" txt_i="18345" txt_f="18360">) and protein (</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="28202" xml_f="28204" txt_i="18360" txt_f="18362">13</offsets></xref><offsets xml_i="28211" xml_f="28277" txt_i="18362" txt_f="18428">). Consistent with our previous report in healthy older subjects (</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="28309" xml_f="28311" txt_i="18428" txt_f="18430">17</offsets></xref><offsets xml_i="28318" xml_f="28334" txt_i="18430" txt_f="18446">), ingestion of </offsets><sc><offsets xml_i="28338" xml_f="28339" txt_i="18446" txt_f="18447">d</offsets></sc><offsets xml_i="28344" xml_f="28666" txt_i="18447" txt_f="18769">-xylose resulted in a modest increase in blood glucose and serum insulin, possibly as a result of enhanced gluconeogenesis. Sucralose was selected as a sweet-tasting negative control, since we have shown that this artificial sweetener when given acutely has no effect on either the secretion of GLP-1 or gastric emptying (</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="28698" xml_f="28700" txt_i="18769" txt_f="18771">21</offsets></xref><offsets xml_i="28707" xml_f="28708" txt_i="18771" txt_f="18772">,</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="28740" xml_f="28742" txt_i="18772" txt_f="18774">22</offsets></xref><offsets xml_i="28749" xml_f="29015" txt_i="18774" txt_f="19040">), and indeed in the current study, there was no increase in intact GLP-1 before the meal on the days when sucralose was given. The osmolarity of the preloads could not readily be matched without changing the taste and this may have contributed to the effect of the </offsets><sc><offsets xml_i="29019" xml_f="29020" txt_i="19040" txt_f="19041">d</offsets></sc><offsets xml_i="29025" xml_f="29062" txt_i="19041" txt_f="19078">-xylose preload on gastric emptying (</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="29094" xml_f="29096" txt_i="19078" txt_f="19080">28</offsets></xref><offsets xml_i="29103" xml_f="29168" txt_i="19080" txt_f="19145">) but is unlikely to account for differences in GLP-1 secretion (</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="29200" xml_f="29202" txt_i="19145" txt_f="19147">22</offsets></xref><offsets xml_i="29209" xml_f="29211" txt_i="19147" txt_f="19149">).</offsets></p><p><offsets xml_i="29218" xml_f="29231" txt_i="19150" txt_f="19163">As expected, </offsets><sc><offsets xml_i="29235" xml_f="29236" txt_i="19163" txt_f="19164">d</offsets></sc><offsets xml_i="29241" xml_f="29463" txt_i="19164" txt_f="19386">-xylose was associated with stimulation of GLP-1 in advance of the meal. It has been postulated that intestinal fermentation to form free fatty acids represents an important mechanism for the stimulation of GLP-1 release (</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="29495" xml_f="29497" txt_i="19386" txt_f="19388">29</offsets></xref><offsets xml_i="29504" xml_f="29601" txt_i="19388" txt_f="19485">); the latter could be indirectly quantified by resultant hydrogen production in breath samples (</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="29633" xml_f="29635" txt_i="19485" txt_f="19487">16</offsets></xref><offsets xml_i="29642" xml_f="29846" txt_i="19487" txt_f="19691">). Our demonstration of a relationship between GLP-1 concentrations and hydrogen production is consistent with this concept. However, the fact that GLP-1 concentrations began to increase within 20 min of </offsets><sc><offsets xml_i="29850" xml_f="29851" txt_i="19691" txt_f="19692">d</offsets></sc><offsets xml_i="29856" xml_f="29945" txt_i="19692" txt_f="19781">-xylose ingestion suggests that other mechanisms, involving, for example, the passage of </offsets><sc><offsets xml_i="29949" xml_f="29950" txt_i="19781" txt_f="19782">d</offsets></sc><offsets xml_i="29955" xml_f="30020" txt_i="19782" txt_f="19847">-xylose through the monosaccharide transporters GLUT2 and GLUT3 (</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="30052" xml_f="30054" txt_i="19847" txt_f="19849">30</offsets></xref><offsets xml_i="30061" xml_f="30191" txt_i="19849" txt_f="19979">), are likely involved. It may appear surprising that plasma intact GLP-1 levels after the potato meal did not differ between the </offsets><sc><offsets xml_i="30195" xml_f="30196" txt_i="19979" txt_f="19980">d</offsets></sc><offsets xml_i="30201" xml_f="30341" txt_i="19980" txt_f="20120">-xylose and control preload study days, when sitagliptin was not given. However, the magnitude of GLP-1 secretion is dependent on the rate (</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="30373" xml_f="30375" txt_i="20120" txt_f="20122">31</offsets></xref><offsets xml_i="30382" xml_f="30394" txt_i="20122" txt_f="20134">) and load (</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="30426" xml_f="30428" txt_i="20134" txt_f="20136">32</offsets></xref><offsets xml_i="30435" xml_f="30534" txt_i="20136" txt_f="20235">) of nutrient entry to the small intestine, so that the slowing of gastric emptying induced by the </offsets><sc><offsets xml_i="30538" xml_f="30539" txt_i="20235" txt_f="20236">d</offsets></sc><offsets xml_i="30544" xml_f="30659" txt_i="20236" txt_f="20351">-xylose preload may well have attenuated the component of the postprandial GLP-1 response attributable to the meal.</offsets></p><p><offsets xml_i="30666" xml_f="30909" txt_i="20352" txt_f="20595">We observed that the magnitude of the initial postprandial glycemic excursion was inversely related to the gastric half-emptying time, consistent with evidence that the rate of gastric emptying is a major determinant of postprandial glycemia (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="30940" xml_f="30941" txt_i="20595" txt_f="20596">4</offsets></xref><offsets xml_i="30948" xml_f="30949" txt_i="20596" txt_f="20597">,</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="30980" xml_f="30981" txt_i="20597" txt_f="20598">5</offsets></xref><offsets xml_i="30988" xml_f="31064" txt_i="20598" txt_f="20674">). In the absence of sitagliptin, the reduction in postprandial glycemia by </offsets><sc><offsets xml_i="31068" xml_f="31069" txt_i="20674" txt_f="20675">d</offsets></sc><offsets xml_i="31074" xml_f="31305" txt_i="20675" txt_f="20906">-xylose is probably attributable mainly to the slowing of gastric emptying, since postprandial intact GLP-1 concentrations were no greater than on the control day. The observed decrease in postprandial insulin concentrations after </offsets><sc><offsets xml_i="31309" xml_f="31310" txt_i="20906" txt_f="20907">d</offsets></sc><offsets xml_i="31315" xml_f="31540" txt_i="20907" txt_f="21132">-xylose in contrast to control, particularly when corrected for differences in blood glucose (i.e., the insulin-to-glucose ratio), is consistent with what would be expected when gastric emptying of the potato meal is slower (</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="31572" xml_f="31574" txt_i="21132" txt_f="21134">12</offsets></xref><offsets xml_i="31581" xml_f="31583" txt_i="21134" txt_f="21136">).</offsets></p><p><offsets xml_i="31590" xml_f="31632" txt_i="21137" txt_f="21179">The slowing of gastric emptying after the </offsets><sc><offsets xml_i="31636" xml_f="31637" txt_i="21179" txt_f="21180">d</offsets></sc><offsets xml_i="31642" xml_f="31881" txt_i="21180" txt_f="21419">-xylose preload was associated with stimulation of GLP-1 in advance of the meal, although postprandial intact GLP-1 concentrations were not increased in the absence of sitagliptin. Since endogenous GLP-1 is known to slow gastric emptying (</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="31912" xml_f="31913" txt_i="21419" txt_f="21420">9</offsets></xref><offsets xml_i="31920" xml_f="32000" txt_i="21420" txt_f="21500">), the elevated GLP-1 may have contributed to the slower gastric emptying after </offsets><sc><offsets xml_i="32004" xml_f="32005" txt_i="21500" txt_f="21501">d</offsets></sc><xref ref-type="bibr" rid="B33"><offsets xml_i="32042" xml_f="32044" txt_i="21501" txt_f="21503">33</offsets></xref><offsets xml_i="32051" xml_f="32243" txt_i="21503" txt_f="21695">). This is likely to be because gastric emptying is modulated by multiple mechanisms. For example, acute hyperglycemia, even within the physiological range, is known to slow gastric emptying (</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="32275" xml_f="32277" txt_i="21695" txt_f="21697">34</offsets></xref><offsets xml_i="32284" xml_f="32336" txt_i="21697" txt_f="21749">), and sitagliptin, particularly when combined with </offsets><sc><offsets xml_i="32340" xml_f="32341" txt_i="21749" txt_f="21750">d</offsets></sc><offsets xml_i="32346" xml_f="32725" txt_i="21750" txt_f="22129">-xylose, potently decreased postprandial glycemia. Moreover, peptide YY (PYY), which is cosecreted with GLP-1 from enteroendocrone L cells, has the capacity to slow gastric emptying. PYY 1-36 and 3-36 are the predominant biologically active forms in the circulation; the latter is formed from degradation of PYY 1-36 by DPP-4 and is reportedly more potent at retarding emptying (</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="32757" xml_f="32759" txt_i="22129" txt_f="22131">35</offsets></xref><offsets xml_i="32766" xml_f="32868" txt_i="22131" txt_f="22233">). Therefore, DPP-4 inhibition might, to some extent, blunt PYY- mediated slowing of gastric emptying.</offsets></p><p><offsets xml_i="32875" xml_f="33138" txt_i="22234" txt_f="22497">In contrast, addition of sitagliptin did not affect gastric emptying but was associated with lowering of postprandial glycemia. Despite the fact that plasma intact GLP-1 concentrations were increased after sitagliptin, particularly when given in combination with </offsets><sc><offsets xml_i="33142" xml_f="33143" txt_i="22497" txt_f="22498">d</offsets></sc><offsets xml_i="33148" xml_f="33323" txt_i="22498" txt_f="22673">-xylose, the insulin response to the meal did not increase in parallel. This is partly accounted for by the fact that the insulinotropic effect of GLP-1 is glucose dependent (</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="33355" xml_f="33357" txt_i="22673" txt_f="22675">36</offsets></xref><offsets xml_i="33364" xml_f="33610" txt_i="22675" txt_f="22921">), but there is also evidence that mechanisms other than insulin secretion are likely to be important in mediating the glucose-lowering effect of GLP-1; the latter include suppression of both glucagon secretion and endogenous glucose production (</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="33642" xml_f="33644" txt_i="22921" txt_f="22923">37</offsets></xref><offsets xml_i="33651" xml_f="33652" txt_i="22923" txt_f="22924">,</offsets><xref ref-type="bibr" rid="B38"><offsets xml_i="33684" xml_f="33686" txt_i="22924" txt_f="22926">38</offsets></xref><offsets xml_i="33693" xml_f="33741" txt_i="22926" txt_f="22974">) and enhancement of peripheral glucose uptake (</offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="33773" xml_f="33775" txt_i="22974" txt_f="22976">39</offsets></xref><offsets xml_i="33782" xml_f="33784" txt_i="22976" txt_f="22978">).</offsets></p><p><offsets xml_i="33791" xml_f="34304" txt_i="22979" txt_f="23492">It is noteworthy that there has been little consideration of how dietary intake interacts with the actions of DPP-4 inhibitors. The current study is therefore novel in demonstrating how consumption of a specific nutrient can improve the efficacy of a DPP-4 inhibitor for reducing postprandial glycemia. Although the number of subjects studied was relatively small, the observed effects were consistent between subjects and were in keeping with previous observations relating to the slowing of gastric emptying by </offsets><sc><offsets xml_i="34308" xml_f="34309" txt_i="23492" txt_f="23493">d</offsets></sc><offsets xml_i="34314" xml_f="34323" txt_i="23493" txt_f="23502">-xylose (</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="34355" xml_f="34357" txt_i="23502" txt_f="23504">17</offsets></xref><offsets xml_i="34364" xml_f="34403" txt_i="23504" txt_f="23543">) and glucose lowering by sitagliptin (</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="34435" xml_f="34437" txt_i="23543" txt_f="23545">20</offsets></xref><offsets xml_i="34444" xml_f="34844" txt_i="23545" txt_f="23945">). Our study represents an acute intervention in a relatively well-controlled group of patients with type 2 diabetes managed by diet alone. In view of the positive outcomes, it would be of particular interest to investigate this approach in type 2 diabetic patients taking metformin, given the synergistic effect of DPP-4 inhibitors with metformin for increasing intact GLP-1 and improving glycemia (</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="34876" xml_f="34878" txt_i="23945" txt_f="23947">40</offsets></xref><offsets xml_i="34885" xml_f="35004" txt_i="23947" txt_f="24066">), and to extend our observations to larger and more diverse groups of type 2 diabetic patients over a longer duration.</offsets></p></sec></body><back><fn-group><fn id="fn1"><p>Clinical trial reg. no. ACTRN12612001131842, <ext-link ext-link-type="uri" xlink:href="http://www.anzctr.org.au">www.anzctr.org.au</ext-link>.</p></fn></fn-group><ack><title>Acknowledgments</title><p>This work was funded by a grant awarded by the National Health and Medical Research Council of Australia (grant no. 627139).</p><p>No potential conflicts of interest relevant to this article were reported.</p><p>T.W. was involved in study design and coordination, subject recruitment, data collection and interpretation, statistical analysis, and drafting of the manuscript; critically reviewed the manuscript; and approved the publication of the final version of the manuscript. M.J.B. assisted with data collection and breath hydrogen analysis, critically reviewed the manuscript, and approved the publication of the final version of the manuscript. B.R.Z. assisted in data collection, critically reviewed the manuscript, and approved the publication of the final version of the manuscript. S.D.S. performed insulin and intact GLP-1 assays, critically reviewed the manuscript, and approved the publication of the final version of the manuscript. M.B. performed the gastric emptying analysis, critically reviewed the manuscript, and approved the publication of the final version of the manuscript. K.L.J. and M.H. were involved in conception of the study and data interpretation, critically reviewed the manuscript, and approved the publication of the final version of the manuscript. C.K.R. was involved in conception and design of the study and data analysis and interpretation, had overall responsibility for the study, critically reviewed the manuscript, and approved the publication of the final version of the manuscript. C.K.R. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p>Parts of this study were presented in abstract form at the Annual Meeting of the European Association for the Study of Diabetes, Berlin, Germany, 1–5 October 2012.</p><p>The authors thank K. Lange for expert statistical advice and A. Lam (Royal Adelaide Hospital Pharmacy) for assistance in preparation and blinding of the treatments.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inzucchi</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><etal></etal></person-group>
<article-title>Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</article-title>. <source>Diabetologia</source>
<year>2012</year>;<volume>55</volume>:<fpage>1577</fpage>–<lpage>1596</lpage><pub-id pub-id-type="pmid">22526604</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Kebbi</surname><given-names>IM</given-names></name><name><surname>Ziemer</surname><given-names>DC</given-names></name><name><surname>Cook</surname><given-names>CB</given-names></name><name><surname>Gallina</surname><given-names>DL</given-names></name><name><surname>Barnes</surname><given-names>CS</given-names></name><name><surname>Phillips</surname><given-names>LS</given-names></name></person-group>
<article-title>Utility of casual postprandial glucose levels in type 2 diabetes management</article-title>. <source>Diabetes Care</source>
<year>2004</year>;<volume>27</volume>:<fpage>335</fpage>–<lpage>339</lpage><pub-id pub-id-type="pmid">14747210</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaikomin</surname><given-names>R</given-names></name><name><surname>Rayner</surname><given-names>CK</given-names></name><name><surname>Jones</surname><given-names>KL</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name></person-group>
<article-title>Upper gastrointestinal function and glycemic control in diabetes mellitus</article-title>. <source>World J Gastroenterol</source>
<year>2006</year>;<volume>12</volume>:<fpage>5611</fpage>–<lpage>5621</lpage><pub-id pub-id-type="pmid">17007012</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Edelbroek</surname><given-names>MA</given-names></name><name><surname>Wishart</surname><given-names>JM</given-names></name><name><surname>Straathof</surname><given-names>JW</given-names></name></person-group>
<article-title>Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects</article-title>. <source>Diabetologia</source>
<year>1993</year>;<volume>36</volume>:<fpage>857</fpage>–<lpage>862</lpage><pub-id pub-id-type="pmid">8405758</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>KL</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Carney</surname><given-names>BI</given-names></name><name><surname>Wishart</surname><given-names>JM</given-names></name><name><surname>Guha</surname><given-names>S</given-names></name><name><surname>Green</surname><given-names>L</given-names></name></person-group>
<article-title>Gastric emptying in early noninsulin-dependent diabetes mellitus</article-title>. <source>J Nucl Med</source>
<year>1996</year>;<volume>37</volume>:<fpage>1643</fpage>–<lpage>1648</lpage><pub-id pub-id-type="pmid">8862300</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Vilsbøll</surname><given-names>T</given-names></name><name><surname>Deacon</surname><given-names>CF</given-names></name></person-group>
<article-title>The incretin system and its role in type 2 diabetes mellitus</article-title>. <source>Mol Cell Endocrinol</source>
<year>2009</year>;<volume>297</volume>:<fpage>127</fpage>–<lpage>136</lpage><pub-id pub-id-type="pmid">18786605</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Stöckmann</surname><given-names>F</given-names></name><name><surname>Ebert</surname><given-names>R</given-names></name><name><surname>Creutzfeldt</surname><given-names>W</given-names></name></person-group>
<article-title>Reduced incretin effect in type 2 (non-insulin-dependent) diabetes</article-title>. <source>Diabetologia</source>
<year>1986</year>;<volume>29</volume>:<fpage>46</fpage>–<lpage>52</lpage><pub-id pub-id-type="pmid">3514343</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Heimesaat</surname><given-names>MM</given-names></name><name><surname>Orskov</surname><given-names>C</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Ebert</surname><given-names>R</given-names></name><name><surname>Creutzfeldt</surname><given-names>W</given-names></name></person-group>
<article-title>Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus</article-title>. <source>J Clin Invest</source>
<year>1993</year>;<volume>91</volume>:<fpage>301</fpage>–<lpage>307</lpage><pub-id pub-id-type="pmid">8423228</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deane</surname><given-names>AM</given-names></name><name><surname>Nguyen</surname><given-names>NQ</given-names></name><name><surname>Stevens</surname><given-names>JE</given-names></name><etal></etal></person-group>
<article-title>Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2010</year>;<volume>95</volume>:<fpage>215</fpage>–<lpage>221</lpage><pub-id pub-id-type="pmid">19892837</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schirra</surname><given-names>J</given-names></name><name><surname>Göke</surname><given-names>B</given-names></name></person-group>
<article-title>The physiological role of GLP-1 in human: incretin, ileal brake or more?</article-title>
<source>Regul Pept</source>
<year>2005</year>;<volume>128</volume>:<fpage>109</fpage>–<lpage>115</lpage><pub-id pub-id-type="pmid">15780430</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Silva</surname><given-names>A</given-names></name><name><surname>Salem</surname><given-names>V</given-names></name><name><surname>Long</surname><given-names>CJ</given-names></name><etal></etal></person-group>
<article-title>The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans</article-title>. <source>Cell Metab</source>
<year>2011</year>;<volume>14</volume>:<fpage>700</fpage>–<lpage>706</lpage><pub-id pub-id-type="pmid">22000927</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentilcore</surname><given-names>D</given-names></name><name><surname>Chaikomin</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>KL</given-names></name><etal></etal></person-group>
<article-title>Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2006</year>;<volume>91</volume>:<fpage>2062</fpage>–<lpage>2067</lpage><pub-id pub-id-type="pmid">16537685</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Stevens</surname><given-names>JE</given-names></name><name><surname>Cukier</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes</article-title>. <source>Diabetes Care</source>
<year>2009</year>;<volume>32</volume>:<fpage>1600</fpage>–<lpage>1602</lpage><pub-id pub-id-type="pmid">19542012</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>BR</given-names></name><name><surname>Bound</surname><given-names>MJ</given-names></name><etal></etal></person-group>
<article-title>Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans</article-title>. <source>Am J Clin Nutr</source>
<year>2012</year>;<volume>95</volume>:<fpage>78</fpage>–<lpage>83</lpage><pub-id pub-id-type="pmid">22158727</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fordtran</surname><given-names>JS</given-names></name><name><surname>Soergel</surname><given-names>KH</given-names></name><name><surname>Ingelfinger</surname><given-names>FJ</given-names></name></person-group>
<article-title>Intestinal absorption of D-xylose in man</article-title>. <source>N Engl J Med</source>
<year>1962</year>;<volume>267</volume>:<fpage>274</fpage>–<lpage>279</lpage><pub-id pub-id-type="pmid">13894031</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>RM</given-names></name><name><surname>Ehrenpreis</surname><given-names>ED</given-names></name></person-group>
<article-title>D-xylose testing</article-title>. <source>J Clin Gastroenterol</source>
<year>1999</year>;<volume>29</volume>:<fpage>143</fpage>–<lpage>150</lpage><pub-id pub-id-type="pmid">10478874</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanis</surname><given-names>L</given-names></name><name><surname>Hausken</surname><given-names>T</given-names></name><name><surname>Gentilcore</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Comparative effects of glucose and xylose on blood pressure, gastric emptying and incretin hormones in healthy older subjects</article-title>. <source>Br J Nutr</source>
<year>2011</year>;<volume>105</volume>:<fpage>1644</fpage>–<lpage>1651</lpage><pub-id pub-id-type="pmid">21294929</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qualmann</surname><given-names>C</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Orskov</surname><given-names>C</given-names></name><name><surname>Creutzfeldt</surname><given-names>W</given-names></name></person-group>
<article-title>Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)</article-title>. <source>Scand J Gastroenterol</source>
<year>1995</year>;<volume>30</volume>:<fpage>892</fpage>–<lpage>896</lpage><pub-id pub-id-type="pmid">8578189</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>DJ</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name></person-group>
<article-title>The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes</article-title>. <source>Lancet</source>
<year>2006</year>;<volume>368</volume>:<fpage>1696</fpage>–<lpage>1705</lpage><pub-id pub-id-type="pmid">17098089</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahrén</surname><given-names>B</given-names></name></person-group>
<article-title>DPP-4 inhibitors</article-title>. <source>Best Pract Res Clin Endocrinol Metab</source>
<year>2007</year>;<volume>21</volume>:<fpage>517</fpage>–<lpage>533</lpage><pub-id pub-id-type="pmid">18054733</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Bellon</surname><given-names>M</given-names></name><name><surname>Wishart</surname><given-names>JM</given-names></name><etal></etal></person-group>
<article-title>Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>
<year>2009</year>;<volume>296</volume>:<fpage>G735</fpage>–<lpage>G739</lpage><pub-id pub-id-type="pmid">19221011</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Checklin</surname><given-names>HL</given-names></name><etal></etal></person-group>
<article-title>Effect of the artificial sweetener, sucralose, on small intestinal glucose absorption in healthy human subjects</article-title>. <source>Br J Nutr</source>
<year>2010</year>;<volume>104</volume>:<fpage>803</fpage>–<lpage>806</lpage><pub-id pub-id-type="pmid">20420761</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghoos</surname><given-names>YF</given-names></name><name><surname>Maes</surname><given-names>BD</given-names></name><name><surname>Geypens</surname><given-names>BJ</given-names></name><etal></etal></person-group>
<article-title>Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test</article-title>. <source>Gastroenterology</source>
<year>1993</year>;<volume>104</volume>:<fpage>1640</fpage>–<lpage>1647</lpage><pub-id pub-id-type="pmid">8500721</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>CG</given-names></name><name><surname>Bartholomeusz</surname><given-names>FD</given-names></name><name><surname>Bellon</surname><given-names>M</given-names></name><name><surname>Chatterton</surname><given-names>BE</given-names></name></person-group>
<article-title>Simultaneous <sup>13</sup>C/14C dual isotope breath test measurement of gastric emptying of solid and liquid in normal subjects and patients: comparison with scintigraphy</article-title>. <source>Nucl Med Rev Cent East Eur</source>
<year>2003</year>;<volume>6</volume>:<fpage>29</fpage>–<lpage>33</lpage><pub-id pub-id-type="pmid">14600930</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>HF</given-names></name><name><surname>Burt</surname><given-names>E</given-names></name><name><surname>Dowling</surname><given-names>K</given-names></name><name><surname>Davidson</surname><given-names>G</given-names></name><name><surname>Brooks</surname><given-names>DA</given-names></name><name><surname>Butler</surname><given-names>RN</given-names></name></person-group>
<article-title>Effect of age on fructose malabsorption in children presenting with gastrointestinal symptoms</article-title>. <source>J Pediatr Gastroenterol Nutr</source>
<year>2011</year>;<volume>52</volume>:<fpage>581</fpage>–<lpage>584</lpage><pub-id pub-id-type="pmid">21502829</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolever</surname><given-names>TM</given-names></name></person-group>
<article-title>Effect of blood sampling schedule and method of calculating the area under the curve on validity and precision of glycaemic index values</article-title>. <source>Br J Nutr</source>
<year>2004</year>;<volume>91</volume>:<fpage>295</fpage>–<lpage>301</lpage><pub-id pub-id-type="pmid">14756916</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Standl</surname><given-names>E</given-names></name><name><surname>Schnell</surname><given-names>O</given-names></name><name><surname>Ceriello</surname><given-names>A</given-names></name></person-group>
<article-title>Postprandial hyperglycemia and glycemic variability: should we care?</article-title>
<source>Diabetes Care</source>
<year>2011</year>;<volume>34</volume>(<issue>Suppl. 2</issue>):<fpage>S120</fpage>–<lpage>S127</lpage><pub-id pub-id-type="pmid">21525442</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>GR</given-names></name><name><surname>Cochrane</surname><given-names>GM</given-names></name><name><surname>Corbett</surname><given-names>GA</given-names></name><name><surname>Hunt</surname><given-names>JN</given-names></name><name><surname>Roberts</surname><given-names>SK</given-names></name></person-group>
<article-title>Actions of glucose and potassium chloride on osmoreceptors slowing gastric emptying</article-title>. <source>J Physiol</source>
<year>1974</year>;<volume>237</volume>:<fpage>183</fpage>–<lpage>186</lpage><pub-id pub-id-type="pmid">4822585</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Rayner</surname><given-names>CK</given-names></name><name><surname>Jones</surname><given-names>K</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name></person-group>
<article-title>Dietary effects on incretin hormone secretion</article-title>. <source>Vitam Horm</source>
<year>2010</year>;<volume>84</volume>:<fpage>81</fpage>–<lpage>110</lpage><pub-id pub-id-type="pmid">21094897</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naula</surname><given-names>CM</given-names></name><name><surname>Logan</surname><given-names>FJ</given-names></name><name><surname>Wong</surname><given-names>PE</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name><name><surname>Burchmore</surname><given-names>RJ</given-names></name></person-group>
<article-title>A glucose transporter can mediate ribose uptake: definition of residues that confer substrate specificity in a sugar transporter</article-title>. <source>J Biol Chem</source>
<year>2010</year>;<volume>285</volume>:<fpage>29721</fpage>–<lpage>29728</lpage><pub-id pub-id-type="pmid">20601430</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaikomin</surname><given-names>R</given-names></name><name><surname>Doran</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>KL</given-names></name><etal></etal></person-group>
<article-title>Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2005</year>;<volume>289</volume>:<fpage>E504</fpage>–<lpage>E507</lpage><pub-id pub-id-type="pmid">15886226</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilichiewicz</surname><given-names>AN</given-names></name><name><surname>Chaikomin</surname><given-names>R</given-names></name><name><surname>Brennan</surname><given-names>IM</given-names></name><etal></etal></person-group>
<article-title>Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2007</year>;<volume>293</volume>:<fpage>E743</fpage>–<lpage>E753</lpage><pub-id pub-id-type="pmid">17609258</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>JE</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Rayner</surname><given-names>CK</given-names></name><name><surname>Jones</surname><given-names>KL</given-names></name></person-group>
<article-title>The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2012</year>;<volume>36</volume>:<fpage>379</fpage>–<lpage>390</lpage><pub-id pub-id-type="pmid">22738299</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schvarcz</surname><given-names>E</given-names></name><name><surname>Palmér</surname><given-names>M</given-names></name><name><surname>Aman</surname><given-names>J</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Stridsberg</surname><given-names>M</given-names></name><name><surname>Berne</surname><given-names>C</given-names></name></person-group>
<article-title>Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus</article-title>. <source>Gastroenterology</source>
<year>1997</year>;<volume>113</volume>:<fpage>60</fpage>–<lpage>66</lpage><pub-id pub-id-type="pmid">9207262</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname><given-names>AB</given-names></name><name><surname>Grybäck</surname><given-names>P</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><etal></etal></person-group>
<article-title>Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man</article-title>. <source>Regul Pept</source>
<year>2009</year>;<volume>158</volume>:<fpage>57</fpage>–<lpage>62</lpage><pub-id pub-id-type="pmid">19651163</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Gromada</surname><given-names>J</given-names></name></person-group>
<article-title>Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2004</year>;<volume>287</volume>:<fpage>E199</fpage>–<lpage>E206</lpage><pub-id pub-id-type="pmid">15271645</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prigeon</surname><given-names>RL</given-names></name><name><surname>Quddusi</surname><given-names>S</given-names></name><name><surname>Paty</surname><given-names>B</given-names></name><name><surname>D’Alessio</surname><given-names>DA</given-names></name></person-group>
<article-title>Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2003</year>;<volume>285</volume>:<fpage>E701</fpage>–<lpage>E707</lpage><pub-id pub-id-type="pmid">12773303</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muscelli</surname><given-names>E</given-names></name><name><surname>Casolaro</surname><given-names>A</given-names></name><name><surname>Gastaldelli</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2012</year>;<volume>97</volume>:<fpage>2818</fpage>–<lpage>2826</lpage><pub-id pub-id-type="pmid">22685234</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edgerton</surname><given-names>DS</given-names></name><name><surname>Johnson</surname><given-names>KM</given-names></name><name><surname>Neal</surname><given-names>DW</given-names></name><etal></etal></person-group>
<article-title>Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog</article-title>. <source>Diabetes</source>
<year>2009</year>;<volume>58</volume>:<fpage>243</fpage>–<lpage>249</lpage><pub-id pub-id-type="pmid">18840785</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migoya</surname><given-names>EM</given-names></name><name><surname>Bergeron</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>JL</given-names></name><etal></etal></person-group>
<article-title>Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1</article-title>. <source>Clin Pharmacol Ther</source>
<year>2010</year>;<volume>88</volume>:<fpage>801</fpage>–<lpage>808</lpage><pub-id pub-id-type="pmid">21048706</pub-id></mixed-citation></ref></ref-list></back></article>